#AI #South Korea #Seoul #Lunit #ECR 2025

Lunit's Landmark Achievement at ECR 2025

In an exciting milestone for the medical community, Lunit (KRX:328130.KQ), a pioneering force in AI-powered cancer diagnostics, made a powerful statement at the European Congress of Radiology (ECR) 2025 in Vienna, Austria. With an impressive 15 research abstracts accepted for presentation, 13 of these were designated as oral presentations, marking the company's largest and most impactful participation in this prestigious event to date.

This year’s conference, running from February 26 to March 2, brought together experts from around the globe to discuss advancements in radiological practices, and Lunit's presence was a highlight. The high acceptance rate of their studies underscores the growing importance of AI technologies in the realm of cancer screening and detection. Lunit's research continues to set the stage for innovations that could revolutionize cancer care.

Groundbreaking Studies Highlighted

Among the noteworthy presentations was a study aimed at understanding how Lunit INSIGHT MMG, Lunit's AI tool, could replace one radiologist in double readings during mammographic screenings. Presented by Marie Burns Bergan from BreastScreen Norway, this research investigated over one million mammography screenings and assessed the AI's ability to maintain accuracy while alleviating the workload on radiologists.

Key Findings Include:

• - Cancer Detection Rates: AI detected up to 79.9% of cancers at a 10% positivity threshold and maintained a 75.5% detection rate at a 5% threshold, including the identification of 5.7% of interval cancers previously overlooked by traditional methods.
• - Reduced Workload for Radiologists: The integration of AI significantly reduced the workload, allowing radiologists to focus on more complex cases while maintaining high detection accuracy.

The potential of AI to function effectively as a second reader in high-volume mammography programs reveals its capacity to address the current shortages of radiologists, optimizing their involvement in crucial screening processes.

Another standout study led by Jonas Gjesvik from BreastScreen Norway examined the ability of Lunit INSIGHT MMG to predict subclinical breast cancer up to six years before formal diagnosis. This study included a significant cohort of 116,000 women participating in ongoing mammography screenings.

Significant Discoveries from this Research Include:

• - Risk Score Predictions: AI showed a remarkable ability to assign higher risk scores to breasts that later developed cancer, facilitating earlier interventions.
• - Progress Tracking: The analysis revealed that AI's risk scores for diagnosed breast cancers increased significantly across screenings, underscoring its predictive capabilities in clinical settings.

These findings indicate a transformative shift toward personalized screening protocols based on individual risk, enhancing early detection strategies for breast cancer.

Lunit's Vision and Future Implications

As CEO Brandon Suh noted, “This year’s ECR is a watershed moment for Lunit, emphasizing our leadership in AI-driven radiology research. The findings from our studies reinforce the critical role of AI in progressing breast cancer detection and optimizing radiological workflows.” Such advancements signal a future where AI is not only a supportive technology but a central player in diagnostic evaluations and patient outcomes.

Attendees at the ECR conference are encouraged to visit Lunit’s booth AI-19 in the EXPO X1 hall to learn about the latest developments in AI-powered cancer detection and explore potential collaborations in this exciting field.

Noteworthy Presentations by Lunit at ECR 2025

1. Replacing One Radiologist - Impact analysis in mammography screening.
2. Using AI for Early Detection - Subclinical breast cancer identification.
3. Associations of Breast Density with Cancer Risk - Insights from the Dutch cohort study.

Founded in 2013, Lunit remains steadfast in its mission to conquer cancer, utilizing AI technologies to enhance medical imaging and provide tailored treatment options. Its solutions are currently utilized by over 4,800 healthcare organizations worldwide, further cementing its role as a cornerstone in the fight against cancer. Discover more about their initiatives at lunit.io.